1Miller K, Raabe N, Trachtenberg J, et al. ZD1839, an epidermal factor receptor tyrosine kinase inhibitor (EGFR-TKI) ,is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refactory cancer ( HRPC ) [ J ]. Proc ESMO,2002,91 :abstr 3270.
2Wu YL, Yang XN, Gu LJ. The characteristics of patients with nonsmall cell lung cancer with complete response treated with ZD1839[J]. Proc ASCO ,2003,22:2770a.
3Burris HA 3rd, Moore M J, Andersen J ,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [ J ].Clin Oncol, 1997,15 ( 6 ) : 2403 - 2413.
4Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life- in non-small cell lung cancer : a review of the hterature and future directions[ J]. Clin Cancer Res, 1998,4~1087 - 1100.
5Dy GK, Adjei AA. Novel largets for lung cancer therapy[ M ]. Part 1. J Clin Oncol,2002,20:2881 -2894.
6Barton J,Blackledge G,Wakeling A. Growth factors and their receptors: nee, targets for prostate cancer therapy[J]. Urology,2001,58( 2 Suppl 1) : 114 - 122.
7Fubuoka M, Yano S, Graccone G, et al. Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer[ J ]. Clin Oncolol,2003,21 ( 12 ) : 2237 - 2246.
8Ciardiello F, Caputo R, Bianco R ,et al. Inhibition of growth factor productioll and angiogenesis in human cancer cells by ZD1839 (Iressa) ,a selective epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Clin Cancer Res,2001,7 ( 5 ) : 1459 - 1465.
9Chan KC, Knox WF, Gandhi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation[J]. Br J Surg,2001,88(3) :412 -418.
10Sirotnak FM,Zakowski MF,Miller VA,et al. Efficacy of cytotoxic agents against human tumor xenografls is markedly enhanced by coadministration of ZD1839 ( Iressa), an inhibitor of EGFR tyrosine kinase[ J ]. Clin Cancer Res,2000,6 ( 12 ) :4885 - 4892.
